** Shares of Pfizer PFE.N are up 2.9% on Mon ahead of the co's analyst and investor call Tuesday to review full-year 2026 financial guidance

** Analysts expecting Q1 2026 EPS of 77 cents and FY 2026 EPS of $3.05, per LSEG data

** Stock is helping to support the S&P 500 healthcare index .SPXHC, which is leading sector gains for the benchmark S&P 500 .SPX with gain of more than 1% on the session

** Bloomberg News reported last week, citing people familiar with the matter, Pfizer will cut over 200 jobs in Switzerland as part of its multi-year cost reduction program

** Also last week, Pfizer said it was partnering with YaoPharma, a subsidiary of China's Shanghai Fosun Pharmaceutical 600196.SS to develop and commercialize an experimental weight-management treatment

** In November, Pfizer lifted its full-year profit forecast for the second time in a row, helped by strong demand for its blockbuster heart treatment and blood thinner

** Shares of Pfizer are nearly flat YTD, compared with a roughly 16% gain in the S&P 500 .SPX

(Reporting by Caroline Valetkevitch)

((caroline.valetkevitch@thomsonreuters.com))